Stay updated with breaking news from Full Fact Sheet. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
21.04.2022 - Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s EVUSHELD (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary ...
EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies - read this article along with other careers information, tips and advice on BioSpace
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities - read this article along with other careers information, tips and advice on BioSpace
Press release content from Business Wire. The AP news staff was not involved in its creation.
16.12.2021 - AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical ...